BioCentury
ARTICLE | Clinical News

BA058-transdermal: Phase II started

October 8, 2012 7:00 AM UTC

Radius began a double-blind, placebo-controlled, international Phase II trial to compare once-daily 50, 100 and 150 µg BA058-TD vs. once-daily 80 µg subcutaneous BA058-Injection ( BA058-SC) for 6 mont...